Pharmacokinetics and pharmacodynamics of suberoylanilide hydroxamic acid in cats

Journal of Veterinary Pharmacology and Therapeutics

Volumn 37, Issue 2, 2014, Pages 196-200

  Mcdonnel, S J ^a   Tell, L A ^b   Murphy, B G ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HISTONE; VORINOSTAT;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EXPOSURE; DRUG HALF LIFE; DRUG TOLERABILITY; EXPERIMENTAL CAT; FEMALE; HISTONE ACETYLATION; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PHARMACOLOGICAL PARAMETERS; PRIORITY JOURNAL; STEADY STATE; TIME TO MAXIMUM PLASMA CONCENTRATION;

ANIMALIA; CANIS FAMILIARIS; FELIDAE;

ANIMALS; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; CATS; CROSS-OVER STUDIES; FEMALE; HALF-LIFE; HYDROXAMIC ACIDS; MALE;

EID: 84895509991     PISSN: 01407783     EISSN: 13652885     Source Type: Journal    
DOI: 10.1111/jvp.12088     Document Type: Article

References (20)

1. Archin, N.M., Liberty, A.L., Kashuba, A.D., Choudhary, S.K., Kuruc, J.D., Crooks, A.M., Parker, D.C., Anderson, E.M., Kearney, M.F., Strain, M.C., Richman, D.D., Hudgens, M.G., Bosch, R.J., Coffin, J.M., Eron, J.J., Hazuda, D.J. & Margolis, D.M. (2012) Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature, 487, 482-485.
2. Balliet, R.M., Chen, G., Gallagher, C.J., Dellinger, R.W., Sun, D. & Lazarus, P. (2009) Characterization of UGTs active against SAHA and association between SAHA glucuronidation activity phenotype with UGT genotype. Cancer Research, 69, 2981-2989.
3. Boumber, Y. & Issa, J.P. (2011) Epigenetics in cancer: what's the future? Oncology (Williston Park), 25, 220-226, 228.
4. Doi, T., Hamaguchi, T., Shirao, K., Chin, K., Hatake, K., Noguchi, K., Otsuki, T., Mehta, A. & Ohtsu, A. (2013) Evaluation of safety, pharmacokinetics, and efficacy of vorinostat, a histone deacetylase inhibitor, in the treatment of gastrointestinal (GI) cancer in a phase I clinical trial. International Journal of Clinical Oncology, 18, 87-95.
5. Ettinger, S.N. (2003) Principles of treatment for feline lymphoma. Clinical Techniques in Small Animal Practice, 18, 98-102.
6. Kavanaugh, S.M., White, L.A. & Kolesar, J.M. (2010) Vorinostat: a novel therapy for the treatment of cutaneous T-cell lymphoma. American Journal of Health System Pharmacy, 67, 793-797.
7. Kelly, W.K., Richon, V.M., O'Connor, O., Curley, T., MacGregor-Curtelli, B., Tong, W., Klang, M., Schwartz, L., Richardson, S., Rosa, E., Drobnjak, M., Cordon-Cordo, C., Chiao, J.H., Rifkind, R., Marks, P.A. & Scher, H. (2003) Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously. Clinical Cancer Research, 9, 3578-3588.
8. Kelly, W.K., O'Connor, O.A., Krug, L.M., Chiao, J.H., Heaney, M., Curley, T., MacGregore-Cortelli, B., Tong, W., Secrist, J.P., Schwartz, L., Richardson, S., Chu, E., Olgac, S., Marks, P.A., Scher, H. & Richon, V.M. (2005) Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. Journal of Clinical Oncology, 23, 3923-3931.
9. Kerr, J.S., Galloway, S., Lagrutta, A., Armstrong, M., Miller, T., Richon, V.M. & Andrews, P.A. (2010) Nonclinical safety assessment of the histone deacetylase inhibitor vorinostat. International Journal of Toxicology, 29, 3-19.
10. Lane, A.A. & Chabner, B.A. (2009) Histone deacetylase inhibitors in cancer therapy. Journal of Clinical Oncology, 27, 5459-5468.
11. Mann, B.S., Johnson, J.R., Cohen, M.H., Justice, R. & Pazdur, R. (2007) FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncologist, 12, 1247-1252.
12. Margolis, D.M. (2011) Histone deacetylase inhibitors and HIV latency. Current Opinion in HIV and AIDS, 6, 25-29.
13. McDonnel, S.J., Sparger, E.E., Luciw, P.A. & Murphy, B.G. (2012a) Pharmacologic reactivation of latent feline immunodeficiency virus ex vivo in peripheral CD4+ T-lymphocytes. Virus Research, 170, 174-179.
14. McDonnel, S.J., Sparger, E.E., Luciw, P.A. & Murphy, B.G. (2012b) Transcriptional regulation of latent feline immunodeficiency virus in peripheral CD4+ T-lymphocytes. Viruses, 4, 878-888.
15. Patel, K., Guichard, S.M. & Jodrell, D.I. (2008) Simultaneous determination of decitabine and vorinostat (Suberoylanilide hydroxamic acid, SAHA) by liquid chromatography tandem mass spectrometry for clinical studies. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences, 863, 19-25.
16. Ramalingam, S.S., Kummar, S., Sarantopoulos, J., Shibata, S., LoRusso, P., Yerk, M., Holleran, J., Lin, Y., Beumer, J.H., Harvey, R.D., Ivy, S.P., Belani, C.P. & Egorin, M.J. (2010) Phase I study of vorinostat in patients with advanced solid tumors and hepatic dysfunction: a National Cancer Institute Organ Dysfunction Working Group study. Journal of Clinical Oncology, 28, 4507-4512.
17. Richman, D.D., Margolis, D.M., Delaney, M., Greene, W.C., Hazuda, D. & Pomerantz, R.J. (2009) The challenge of finding a cure for HIV infection. Science, 323, 1304-1307.
18. Rubin, E.H., Agrawal, N.G., Friedman, E.J., Scott, P., Mazina, K.E., Sun, L., Du, L., Ricker, J.L., Frankel, S.R., Gottesdiener, K.M., Wagner, J.A. & Iwamoto, M. (2006) A study to determine the effects of food and multiple dosing on the pharmacokinetics of vorinostat given orally to patients with advanced cancer. Clinical Cancer Research, 12, 7039-7045.
19. Sandhu, P., Andrews, P.A., Baker, M.P., Koeplinger, K.A., Soli, E.D., Miller, T. & Baillie, T.A. (2007) Disposition of vorinostat, a novel histone deacetylase inhibitor and anticancer agent, in preclinical species. Drug Metabolism Letters, 1, 153-161.
20. Wong, N.S., Seah, E., Wang, L.Z., Yeo, W.L., Yap, H.L., Chuah, B., Lim, Y.W., Ang, P.C., Tai, B.C., Lim, R., Goh, B.C. & Lee, S.C. (2011) Impact of UDP-gluconoryltransferase 2B17 genotype on vorinostat metabolism and clinical outcomes in Asian women with breast cancer. Pharmacogenetics and Genomics, 21, 760-768.